Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stenting And Thrombectomy Systems Fuel Neuro Device Market Growth

Executive Summary

Advances in distally protected carotid artery stenting systems and second-generation cerebral thrombectomy devices will help drive strong growth in the US neurointerventional device market over the next five years. The market, which includes endovascular devices for the treatment of cerebral aneurysms, arteriovenous malformations, stroke, and carotid artery disease, is projected to grow at a compound annual rate of 6.5%, and reach more than $846 million by 2018.

You may also be interested in...



Shionogi Reveals Strategy For COVID-19 Drug Xocova

Shionogi is hoping to demonstrate the efficacy of its oral COVID-19 candidate Xocova through an appropriate primary endpoint in its Phase III trial, while the Japanese firm is also eyeing global expansion for the drug should a world-first domestic approval be granted.

Beiersdorf Is Having Record Year For Sun Care, Seeing China Recovery, But Full-Year Outlook Is Guarded

The Hamburg, Germany-based firm defied economic and political headwinds and China troubles in the fiscal 2022 first half to book organic net sales growth of 10.5% to 4.5bn worldwide. Despite optimism about China recovery, sun care, and its recent Chantecaille acquisition, Beiersdorf is projecting a slowdown in the second half in what remains a volatile operating environment.

Immunogenicity Data Drove Monkeypox Dose-Sparring Decision…It Also Drove Initial Approval

Comfort with the initial approval based on inferred effectiveness may have made the current EUA process more palatable to US FDA officials but means there is a bigger gap in what’s known about the vaccine’s effectiveness overall.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT035827

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel